Product image of Mesar (Olmesartan Medoxomil) supplied by GNH India

Mesar

Active Ingredient:
Olmesartan Medoxomil
Origin:
EU

Mesar (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Mesar, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral administration. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH India supplies Mesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antihypertensive medication.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan medoxomil is an ARB used to treat conditions related to the renin‑angiotensin system, primarily hypertension.

  • Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
  • High blood pressure: assists in achieving target blood pressure levels as part of antihypertensive therapy.
  • Cardiovascular risk management: contributes to risk reduction by controlling blood pressure in at‑risk adults.

How It Works

  • Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition reduces vasoconstriction, aldosterone secretion, and sympathetic activation, leading to relaxation of vascular smooth muscle and decreased peripheral resistance, which lowers blood pressure.

Side Effects

Common Side Effects

  • Dizziness: sensation of light‑headedness, especially after standing.
  • Headache: mild to moderate pain in the head region.
  • Fatigue: feeling unusually tired or weak.
  • Abdominal pain: discomfort or cramping in the stomach area.
  • Nasal congestion: blocked or runny nose.
  • Back pain: soreness in the lower back.

Serious or Rare Side Effects

  • Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
  • Hyperkalemia: elevated potassium levels that can affect heart rhythm.
  • Acute renal failure: sudden loss of kidney function.
  • Severe hypotension: markedly low blood pressure causing faintness.
  • Liver injury: abnormal liver function tests or hepatitis.
  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Precautions & Warnings

Olmesartan medoxomil should be used with caution in specific clinical situations.

  • Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity.
  • Renal impairment: monitor kidney function and adjust therapy as needed.
  • Hepatic impairment: use with caution; assess liver enzymes periodically.
  • Electrolyte imbalance: watch for hyperkalemia, especially when combined with potassium‑sparing agents.
  • Concomitant aliskiren in diabetes: avoid combined use due to increased risk of renal complications.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan medoxomil may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Aliskiren in diabetic patients: combined use can increase renal risk.
  • Dual therapy with ACE inhibitors or other ARBs: may cause excessive hypotension and renal dysfunction.
  • Potassium‑sparing diuretics or supplements: risk of hyperkalemia.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may reduce antihypertensive efficacy and affect renal function.
  • Lithium: can increase lithium serum concentrations, risking toxicity.
  • Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure closely.

Frequently Asked Questions

Mesar contains olmesartan medoxomil, an angiotensin II receptor blocker indicated for the treatment of hypertension in adult patients. By lowering elevated blood pressure, it helps reduce the risk of cardiovascular events associated with high blood pressure.

Olmesartan medoxomil selectively blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels, reduced peripheral resistance, and ultimately a decrease in blood pressure.

The appropriate dose of Mesar is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Mesar is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs the potential risk.

To order Mesar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mesar (olmesartan) belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough. Compared with other ARBs, olmesartan provides once‑daily dosing and a favorable tolerability profile, making it a common choice for patients who cannot tolerate ACE inhibitors.

Mesar should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Mesar is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension, hyperkalemia (high potassium levels), and acute renal impairment. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or signs of kidney dysfunction.

Mesar should not be used by pregnant women, individuals with known hypersensitivity to olmesartan or any component of the formulation, and patients with severe hepatic impairment. Caution is also advised for those with significant renal dysfunction or electrolyte abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT